Omalizumab in Severe Asthma: Indian perspective

Speciality: Pulmonary Medicine

Description:

A warm welcome to all the medical professionals in this interesting session on Omalizumab in Severe Asthma: Indian perspective
Omalizumab, a monoclonal antibody targeting IgE, has emerged as an effective treatment for severe allergic asthma in India. It is particularly beneficial for patients whose asthma is inadequately controlled with standard therapies like inhaled corticosteroids and long-acting bronchodilators. By blocking IgE, which plays a central role in allergic reactions, omalizumab helps reduce the frequency and severity of asthma exacerbations, improving overall control of the condition.
In the Indian context, where pollution and environmental allergens are significant triggers for asthma, omalizumab offers a targeted approach to managing severe cases. Clinical experience in India has shown that patients on omalizumab experience fewer hospitalizations and a better quality of life. However, accessibility and cost remain barriers to widespread use, as biologic therapies can be expensive. Despite these challenges, omalizumab has become an important option for patients with severe allergic asthma who have not responded to conventional treatments, providing hope for improved outcomes in this population.
Therefore, get an overall knowledge of Omalizumab in Severe Asthma: Indian perspective
 

See More Webinars @ Hidoc Webinars